Used in targeted therapy for HER2-positive breast and gastric cancers, this antibody binds to the HER2 receptor with enhanced affinity, particularly in patients with low-affinity FcγRIIIa variants, improving immune-mediated destruction of cancer cells. It is indicated for patients who have received prior anti-HER2 therapies. The antibody promotes antibody-dependent cellular cytotoxicity (ADCC), helping the immune system recognize and kill tumor cells. It is administered intravenously and often used in combination with chemotherapy agents for advanced or metastatic disease. Its design aims to improve clinical response across diverse patient populations regardless of Fc receptor genotype.